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a b s t r a c t
A stroke, or a cerebrovascular accident (CVA) is a life-threatening condition which often results
in permanent or signiﬁcant disability in the adult population. Several classiﬁcations of CVAs
exist, one of them being based on the mechanism of injury of brain tissue: ischemic (85–90%)
and hemorrhagic (10–15%). In a hemorrhagic stroke an intercranial bleeding occurs, leading to
the formation of a focal hematoma typically located in the basal ganglia of the brain (approx.
45% of cases). A common yet underestimated cause of intracerebral hemorrhage is cerebral
small vessel disease with microhemorrhages, including the cerebral amyloid angiopathy
(CAA). This condition is associated with the deposition of amyloid-beta in arterial walls (in
soft meninges, subcortical areas and the cerebral cortex). Research has shown that causes of
hemorrhagic changes in the brain include genetic disorders, such as Down syndrome. The
association is caused by the so-called 'gene dosage effect', as the gene for the precursor protein
for amyloid-beta is located in chromosome 21. We wish to present the case of a 60 year
old patient with Down syndrome who suffered a hemorrhagic stroke without antecedent
hypertension. Based on the history taken, diagnostic imaging and the source literature, a
diagnosis of cerebral amyloid angiopathy as the source of the bleeding was made (however
it must be noted that without a full post-mortem examination, the Boston criteria allow only
for a 'probable cerebral amyloid angiopathy' diagnosis to be made). The authors hereby also
report the need to modify the Boston criteria for cerebral amyloid angiopathy.
# 2015 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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rates due to strokes [3]. The poorest outcomes were associated
with hemorrhagic strokes: the intracerebral hemorrhage
and the subarachnoid hemorrhage [4,5]. Classic risk factors
for intracerebral hemorrhage are hypertension, aneurysms,
vascular malformations, bleeding diatheses, the use of
psychoactive substances, brain tumors and cerebral amyloid
angiopathy, among others [6]. According to the source
literature, the cerebral amyloid angiopathy was found in
approximately one third of patients with lobar intracerebral
hemorrhages [7]. Pathological changes associated with CAA
may be found in patients with Alzheimer's disease as well as
Down syndrome, although their importance in the latter case
is not fully understood. There are reported cases from various
countries, including Poland, of histologically conﬁrmed intra-
cerebral hemorrhages in patients with Down syndrome with
coexisting cerebral amyloid angiopathy [8–10]. In Down
syndrome there is an overexpression of genes located in the
triplicated chromosome 21. In case of APP (amyloid precursor
protein APP) the expression is increased four to ﬁve times in
individuals with DS (Ann N Y Acad Sci. 1993 Sep 24;695:91–102.
Regulation and expression of the Alzheimer's beta/A4 amyloid
protein precursor in health, disease, and Down's syndrome.
Beyreuther K, Pollwein P, Multhaup G, Mönning U, König G,
Dyrks T, Schubert W, Masters CL). This overexpression of APP
is thought to be responsible for Alzheimer's-like dementia in
patients with DS (Neurology 2004; 62:1996–1998, M. Margallo-
Lana, C.M. Morris, A.M. Gibson, et al.). The AD-like dementia
start at the median age of 50 years, which strongly suggests
that beta-amyloid exists not only in the brain but also in small
vessels. However, only 22% of patients suffering from AD have
cerebral microbleeds. (Cerebral microbleeds and Alzheimer's
disease, Charlotte Cordonnier and Wiesje M. van der Flier, in
Cerebral Microbleeds edited by David J. Werring, Cambridge
University Press, London, 2011). The post-mortem examina-
tion of 117 brains of patients with AD revealed signs of CAA
in 97 brains (83%), out of which 30 (25,6%) showed moderate to
severe CAA. Brains in the latter group revealed more ischemic
and hemorrhagic changes compared to the group with little
to no amyloid angiopathy (Neurology. 1996 Jun;46(6):1592–6.Fig. 1 – Hemorrhagic region in early subacute stage in deep stru
and modeling of the lateral ventricle. Also periventricular lacun
B – T2-dependent axial image, C – T1-dependent axial image.Cerebral amyloid angiopathy in the brains of patients with
Alzheimer's disease: the CERAD experience, Part XV. Ellis RJ,
Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D, Heyman A).
The available body of research indicates that there is a
connection between the APP gene expression, CAA and
hemorrhagic strokes.
This study presents the case of a Down syndrome patient;
after taking into consideration the patient's history, patho-
genesis, and additional diagnostic studies, it was possible to
establish an antemortem diagnosis of probable cerebral
amyloid angiopathy based on the Boston criteria. However,
the authors maintain that by applying the Occam's razor
principle, the degree of probability is much higher than the
criteria would lead one to believe.
2. Case report
A 60-year-old patient with Down syndrome (diagnosis based
on patient's phenotype as well as available documentation)
was admitted to the clinic with an acute onset of right-sided
hemiparesis preceded by loss of consciousness. There were no
signs of cranial trauma, nor any information indicative thereof
from the paramedics. Neurological examination on admission
revealed that the patient was conscious, somnolent, with
incoherent speech, had eye deviation towards the left side,
central facial palsy, paralysis of right upper limb and vestigial
movement in right lower limb. Plantar reﬂex was present in
the right lower limb. Deep tendon reﬂexes were diminished on
the right side. The CBC, PT, PTT, LFTs, glucose and BUN values
were within normal limits. A CT scan revealed a hemorrhagic
focus in deep structures of the left hemisphere, which
corresponded to the presented symptoms (Fig. 1) as well as
bilateral lacunae of approx. 6 mm in diameter in basal ganglia.
In addition, calciﬁcations in lenticular nuclei were noted.
The patient was disqualiﬁed from surgical management. Due
to the lack of history of hypertension, a contrast enhanced
head MRI with a susceptibility weighted imaging (SWI)
sequence was ordered to differentiate from other causes of
bleeding, bearing in mind the association between Downctures of the left hemisphere with surrounding edema
ar infarcts can be noticed on both sides. A – CT scan,
Fig. 2 – SWI axial images. The large hemorrhagic region in deep structures of the left hemisphere. The smaller areas of signal
loss in the left occipital lobe indicating bleeding – arrows.
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rhagic focus (43 mm  28 mm  51 mm) in the left hemi-
sphere. The SWI sequence showed small low-signal lesions
scattered subcortically, with the highest concentration in
the left occipital lobe. In addition, periventricular lesions
congruent with vascular changes were noted. An ultrasound
of carotid and vertebral arteries revealed no signiﬁcant
hemodynamic changes (Fig. 2).
The patient's condition ﬂuctuated throughout the hospital
stay. A severe case of pneumonia unresponsive to treatment
developed, which subsequently led to the patient's death a
month later. Due to a known cause of death as well as the
wishes of the patient's family, an autopsy was not performed.
3. Discussion
The Boston criteria (proposed by neurologists studying strokes
in the Boston region and published in 2001) allow only for
the diagnosis of a 'probable amyloid angiopathy' to be made.
However, an evaluation of the criteria showed a 100%
correlation between radiologic changes seen in the CT scan
and/or MRI characteristic for the cerebral amyloid angiopathy,
and changes found in autopsy material [11]. A more recent
study applied and evaluated the Boston criteria to a population
suffering from a hereditary form of amyloidosis, the Dutch-
type cerebral CAA, characterised by a mutation in codon 693 of
the APP gene. Both in the symptomatic and asymptomatic
groups of patients (an improvement on the original 2001 study)
a T2* MRI sequence had a high sensitivity in detecting CAA
lesions. The sensitivity of the Boston criteria improved when
microbleeds were included, and it did not decrease with the
exclusion of hemorrhages in the deep white matter, basal
ganglia, thalamus, and brainstem. (Descriptive Analysis of the
Boston Criteria Applied to a Dutch-Type Cerebral Amyloid
Angiopathy Population van Rooden, MSc; Jeroen van der
Grond, PhD; Rivka van den Boom, MD, PhD; Joost Haan, MD,
PhD; Jennifer Linn, MD; Steven M. Greenberg, MD, PhD;
Mark A. van Buchem, MD, PhD). However, other pathologiespresenting with asymptomatic microbleeds such as Fabry
disease, CADASIL, CARASIL, COL4A1 and COL4A2 mutations
related microangiopathy, or Susac's syndrome [12,13]. The
Boston criteria have not been updated in over a decade,
and they do not take into account the genetic and pathologic
link between Down syndrome and the cerebral amyloid
angiopathy.
According to the authors of this study, a careful evaluation
of the Boston criteria [11], case reports [8–10], imaging studies
and exclusion of other causes of hemorrhage provide an
antemortem diagnosis of cerebral amyloid angiopathy with
a greater degree of probability that the Boston criteria in
isolation. An analogy can be made to the evolution of
diagnostic criteria of Alzheimer disease. It is now acceptable
to make such a diagnosis based on the patient's history,
imaging studies and genetic proﬁling to exclude the trisomy of
the 21 chromosome, without a histopathological conﬁrmation
[14], which several decades ago would not have been possible
[15].
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